دورية أكاديمية
أعرض في EDS

ADCC-activating antibodies correlate with decreased risk of congenital human cytomegalovirus transmission.

التفاصيل البيبلوغرافية
العنوان: ADCC-activating antibodies correlate with decreased risk of congenital human cytomegalovirus transmission.
المؤلفون: Semmes EC; Medical Scientist Training Program, Department of Molecular Genetics and Microbiology, and.; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA., Miller IG; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.; Department of Pediatrics, Weill Cornell Medicine, New York City, New York, USA., Rodgers N; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA., Phan CT; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA., Hurst JH; Department of Pediatrics, Duke University, Durham, North Carolina, USA., Walsh KM; Department of Pediatrics, Duke University, Durham, North Carolina, USA.; Department of Neurosurgery, Duke University, Durham, North Carolina, USA., Stanton RJ; Division of Infection and Immunology, School of Medicine, Cardiff University, Cardiff, United Kingdom., Pollara J; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA., Permar SR; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.; Department of Pediatrics, Weill Cornell Medicine, New York City, New York, USA.
المصدر: JCI insight [JCI Insight] 2023 Jul 10; Vol. 8 (13). Date of Electronic Publication: 2023 Jul 10.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Ann Arbor, Michigan : American Society for Clinical Investigation, [2016]-
مواضيع طبية MeSH: Cytomegalovirus*/physiology , Cytomegalovirus Infections*, Humans ; Antibody-Dependent Cell Cytotoxicity ; Antibodies, Viral ; Immunoglobulin Fc Fragments ; Immunoglobulin G
مستخلص: Human cytomegalovirus (HCMV) is the most common vertically transmitted infection worldwide, yet there are no vaccines or therapeutics to prevent congenital HCMV (cCMV) infection. Emerging evidence indicates that antibody Fc effector functions may be a previously underappreciated component of maternal immunity against HCMV. We recently reported that antibody-dependent cellular phagocytosis (ADCP) and IgG activation of FcγRI/FcγRII were associated with protection against cCMV transmission, leading us to hypothesize that additional Fc-mediated antibody functions may be important. In this same cohort of HCMV-transmitting (n = 41) and nontransmitting (n = 40) mother-infant dyads, we report that higher maternal sera antibody-dependent cellular cytotoxicity (ADCC) activation is also associated with lower risk of cCMV transmission. We investigated the relationship between ADCC and IgG responses against 9 viral antigens and found that ADCC activation correlated most strongly with sera IgG binding to the HCMV immunoevasin protein UL16. Moreover, we determined that higher UL16-specific IgG binding and FcγRIII/CD16 engagement were associated with the greatest risk reduction in cCMV transmission. Our findings indicate that ADCC-activating antibodies against targets such as UL16 may represent an important protective maternal immune response against cCMV infection that can guide future HCMV correlates studies and vaccine or antibody-based therapeutic development.
التعليقات: Update of: medRxiv. 2023 Mar 17;:. (PMID: 36993668)
References: Dev Med Child Neurol. 2017 Dec;59(12):1261-1268. (PMID: 28990181)
J Virol. 2017 Jul 12;91(15):. (PMID: 28490582)
Blood. 2017 Mar 23;129(12):1680-1684. (PMID: 27979823)
Cell. 2019 Jun 27;178(1):202-215.e14. (PMID: 31204102)
J Virol. 2005 Aug;79(16):10330-8. (PMID: 16051825)
Trends Microbiol. 2020 Nov;28(11):900-912. (PMID: 32448762)
J Clin Invest. 2021 Feb 15;131(4):. (PMID: 33586678)
Semin Immunopathol. 2014 Nov;36(6):627-40. (PMID: 25288477)
Sci Transl Med. 2014 Mar 19;6(228):228ra38. (PMID: 24648341)
Cell Host Microbe. 2014 Aug 13;16(2):201-214. (PMID: 25121749)
Front Immunol. 2019 Feb 28;10:332. (PMID: 30873178)
J Virol. 2008 May;82(9):4585-94. (PMID: 18287244)
N Engl J Med. 2021 Jul 29;385(5):436-444. (PMID: 34320288)
Semin Immunopathol. 2017 Nov;39(6):605-613. (PMID: 28971246)
J Infect Dis. 2020 Mar 5;221(Suppl 1):S9-S14. (PMID: 32134480)
PLoS Pathog. 2019 Dec 16;15(12):e1008064. (PMID: 31841557)
Biotechniques. 2008 Dec;45(6):659-62, 664-8. (PMID: 19238796)
Sci Transl Med. 2020 Nov 4;12(568):. (PMID: 33148624)
Front Immunol. 2018 Oct 01;9:2214. (PMID: 30327650)
Vaccine. 2016 Jan 12;34(3):313-9. (PMID: 26657184)
Clin Vaccine Immunol. 2014 Oct;21(10):1377-84. (PMID: 25165026)
Clin Infect Dis. 2021 Aug 16;73(4):e981-e987. (PMID: 33560335)
J Infect Dis. 2022 Nov 1;226(9):1667-1677. (PMID: 35970817)
Nat Rev Immunol. 2008 Jan;8(1):34-47. (PMID: 18064051)
Immunity. 2001 Feb;14(2):123-33. (PMID: 11239445)
J Infect Dis. 2019 Jul 31;220(5):781-791. (PMID: 31050742)
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6273-6278. (PMID: 29686064)
Microorganisms. 2021 Aug 16;9(8):. (PMID: 34442828)
J Virol. 2015 Mar;89(5):2906-17. (PMID: 25540381)
J Matern Fetal Neonatal Med. 2010 Oct;23 Suppl 3:45-8. (PMID: 20807160)
Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4005-10. (PMID: 16537476)
PLoS Pathog. 2014 May 15;10(5):e1004131. (PMID: 24830376)
Nat Rev Immunol. 2020 Feb;20(2):113-127. (PMID: 31666730)
Proc Natl Acad Sci U S A. 2018 May 8;115(19):4998-5003. (PMID: 29691324)
Eur J Immunol. 2001 May;31(5):1428-37. (PMID: 11465099)
J Infect Dis. 2023 Mar 28;227(6):739-741. (PMID: 35876548)
Clin Infect Dis. 2013 Dec;57 Suppl 4:S178-81. (PMID: 24257422)
J Immunol Methods. 2013 Jan 31;387(1-2):21-35. (PMID: 23023090)
New Microbiol. 2019 Jan;42(1):1-20. (PMID: 30671581)
Rev Med Virol. 2019 May;29(3):e2034. (PMID: 30706584)
J Clin Invest. 2022 Aug 15;132(16):. (PMID: 35763348)
J Virol. 2013 Jul;87(13):7717-25. (PMID: 23637420)
J Infect Dis. 2022 Sep 4;226(4):566-575. (PMID: 35876164)
Cell. 2019 Jun 27;178(1):190-201.e11. (PMID: 31204101)
PLoS Pathog. 2018 Apr 9;14(4):e1006987. (PMID: 29630668)
N Engl J Med. 2014 Apr 3;370(14):1316-26. (PMID: 24693891)
J Virol. 2018 Mar 14;92(7):. (PMID: 29343580)
Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3728-3733. (PMID: 30733288)
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6267-6272. (PMID: 29712861)
Elife. 2017 Feb 10;6:. (PMID: 28186488)
Clin Infect Dis. 2013 May;56(9):1232-9. (PMID: 23334811)
iScience. 2019 Feb 22;12:13-26. (PMID: 30677738)
معلومات مُعتمدة: MR/S00971X/1 United Kingdom MRC_ Medical Research Council; R21 CA242439 United States CA NCI NIH HHS; R21 AI147992 United States AI NIAID NIH HHS
فهرسة مساهمة: Keywords: Adaptive immunity; Immunoglobulins; Immunology; Infectious disease; NK cells
المشرفين على المادة: 0 (Antibodies, Viral)
0 (Immunoglobulin Fc Fragments)
0 (Immunoglobulin G)
تواريخ الأحداث: Date Created: 20230710 Date Completed: 20230711 Latest Revision: 20240221
رمز التحديث: 20240221
مُعرف محوري في PubMed: PMC10371338
DOI: 10.1172/jci.insight.167768
PMID: 37427588
قاعدة البيانات: MEDLINE
الوصف
تدمد:2379-3708
DOI:10.1172/jci.insight.167768